HUTCHMED Highlights Data to be Presented at ESMO
HUTCHMED announces multiple clinical data presentations at ESMO Congress 2025, including fruquintinib and savolitinib studies.
Select text to share a quote on X · sign in to keep highlights & notes in your HCM notes
Hong Kong, Shanghai & Florham Park, NJ - Thursday, October 2, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology ("ESMO") Congress 2025, taking place on October 17-21, 2025 in Berlin, Germany.
Results from the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma will be presented in a Mini Oral session. Additionally, further analyses of the fruquintinib FRUSICA-1 study in endometrial cancer and the savolitinib SACHI and SAVANNAH studies in non-small cell lung cancer will be presented during the poster sessions.
Details of the presentations are as follows:
| Abstract title | Presenter / Lead author | Presentation details |
| SPONSORED STUDIES | ||
| Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): results from phase 3 part of a randomized, open-label, active-controlled phase 2/3 study (FRUSICA-2) | Zhenhua Liu (Chengdu, China) | 2592MO Mini Oral Session 1: GU tumours, renal & urothelial Friday, Oct 17, 2025 Karlsruhe Auditorium - Hall 5.2 16:00 - 17:30 CEST |
| A Fruquintinib Expanded Access Program (EAP) to Provide Treatment for Patients With Metastatic Colorectal Cancer (mCRC) | Stefan Kasper-Virchow (Essen, Germany) | 794P Poster Session: Colorectal cancer |
| Fruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a phase 1b/2 study | N. Arvind Dasari (Houston, USA) | 799P Poster Session: Colorectal cancer |
| A novel artificial intelligence (AI) imaging biomarker of tumor vascularity and heterogeneity radiomics to predict survival benefit of fruquintinib vs placebo in metastatic colorectal cancer (mCRC) | Sara Lonardi (Padua, Italy) | 804P Poster Session: Colorectal cancer |
| Safety and tolerability of fruquintinib: Pooled analysis of three placebo-controlled studies in patients with metastatic colorectal cancer | Cathy Eng (Nashville, USA) | 811P Poster Session: Colorectal cancer |
| Association between Metabolic Syndrome (MetS) and clinical outcomes of Fruquintinib plus Sintilimab in Previously Treated Advanced Endometrial Cancer (EMC) Patients with pMMR Status: results from FRUSICA-1 study | Danbo Wang (Shenyang, China) | 1230eP Poster Session: Gynaecological Cancer |
| ctDNA analysis in phase 3 SACHI trial: savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI) | Yongfeng Yu (Shanghai, China) | 1954P Poster Session: NSCLC, metastatic |
| SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi | Quincy Siu-chung Chu (Edmonton, Canada) | 1955P Poster Session: NSCLC, metastatic |
| MET testing and treatment (tx) sequencing after progression on first line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): interim analysis of a global real world (rw) study | Julia Rotow (Boston, USA) | 1956P Poster Session: NSCLC, metastatic |
| INVESTIGATOR-INITIATED STUDIES | ||
| Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated surgical and survival results from the single-arm, phase 2 clinical trial | Fei Ma (Zhengzhou, China) | 2159P Poster Session: Oesophagogastric cancer |
| Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, Phase II Study | Wangjun Liao (Guangzhou, China) | 898eP E-poster Session: Colorectal cancer |
| The efficacy and safety of surufatinib combined with chemotherapy in the first-line treatment of advanced periampullary carcinoma: a single arm, prospective, exploratory clinical study | Qianqian Wang (Nanjing, China) | 929P Poster Session: Developmental therapeutics |
| Surufatinib-Based Late-Line Therapy Outcomes in Recurrent Metastatic NSCLC: Monotherapy and Vinorelbine Combination Regimens | Yanfang Zheng (Guangzhou, China) | 1884P Poster Session: NSCLC, metastatic |
| Surufatinib combined with Toripalimab, Pemetrexed, and Platinum in Advanced Non-Squamous Non-Small Cell Lung Cancer (nsg-NSCLC): Final Phase ll Results from a Single-Center Trial | Wenfeng Fang/ Li Zhang (Guangzhou, China) | 1887P Poster Session: NSCLC, metastatic |
| Efficacy/safety and preliminary scRNA-seq results of surufatinib plus gemcitabine and nab-paclitaxel as neoadjuvant therapy in resectable and borderline resectable pancreatic cancer | Song Gao/ Jihui Hao (Tianjin, China) | 2236P Poster Session: Pancreatic cancer |
| Efficacy and Safety of Surufatinib in Patients with Advanced Soft Tissue Sarcoma After Failure of Anthracycline Chemotherapy and Prior Effective Antiangiogenic Therapy: A Single-Arm, Prospective, Exploratory Phase II Study | Xiaowei Zhang/ Zhiguo Luo (Shanghai, China) | 2716P Poster Session: Sarcoma |
About Fruquintinib
About Savolitinib
About Surufatinib
Medical Information
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.